Insider Selling: Aduro Biotech, Inc. (ADRO) CEO Sells 40,000 Shares of Stock
Aduro Biotech, Inc. (NASDAQ:ADRO) CEO Stephen T. Isaacs sold 40,000 shares of Aduro Biotech stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $10.78, for a total transaction of $431,200.00. Following the sale, the chief executive officer now directly owns 213,921 shares of the company’s stock, valued at approximately $2,306,068.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of Aduro Biotech, Inc. (NASDAQ:ADRO) traded down 0.89% during trading on Wednesday, reaching $11.10. 277,455 shares of the company traded hands. The firm’s 50 day moving average price is $11.18 and its 200-day moving average price is $10.94. Aduro Biotech, Inc. has a 52 week low of $8.75 and a 52 week high of $15.52. The company’s market capitalization is $828.19 million.
Aduro Biotech (NASDAQ:ADRO) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). The business had revenue of $5.90 million for the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. Aduro Biotech’s quarterly revenue was down 84.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.03 earnings per share. Equities analysts anticipate that Aduro Biotech, Inc. will post ($1.35) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: Aduro Biotech, Inc. (ADRO) CEO Sells 40,000 Shares of Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/insider-selling-aduro-biotech-inc-adro-ceo-sells-40000-shares-of-stock.html.
Several analysts have recently weighed in on ADRO shares. Zacks Investment Research raised shares of Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Tuesday, July 4th. Cowen and Company started coverage on shares of Aduro Biotech in a research note on Tuesday, July 18th. They set an “outperform” rating for the company. BidaskClub raised shares of Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. HC Wainwright set a $18.00 price target on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. Finally, Canaccord Genuity set a $30.00 price target on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $19.00.
A number of institutional investors have recently added to or reduced their stakes in ADRO. Wellington Management Group LLP lifted its holdings in Aduro Biotech by 9.1% during the 1st quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock worth $101,571,000 after buying an additional 791,770 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Aduro Biotech by 283.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after buying an additional 275,295 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Aduro Biotech by 330.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock worth $2,545,000 after buying an additional 181,734 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Aduro Biotech by 762.1% during the 1st quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after buying an additional 160,800 shares in the last quarter. Finally, Nexthera Capital LP acquired a new stake in Aduro Biotech during the 2nd quarter worth approximately $1,767,000. Institutional investors own 35.05% of the company’s stock.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.